Start-Ups Swimming ...
Health Care: Drugs
Sucampo Pharmaceuticals Inc. A (SCMP: NASDAQ)
$9.02 0.17 | 1.92%
05/24/13 - 04:00 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 52.02M | 50.66M | 49.24M | 26.71M |
| Receivables | 16.27M | 17.45M | 13.05M | 12.18M |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 2.60M | 3.06M | 0.00 | 0.00 |
| Total Current Assets | 92.91M | 114.92M | 134.54M | 114.78M |
| Property, Plant & Equipment, Gross | 4.51M | 4.11M | 4.03M | 3.59M |
| Accumulated Depreciation & Depletion | 2.97M | 2.44M | 2.00M | 1.35M |
| Property, Plant & Equipment, Net | 1.54M | 1.67M | 2.02M | 2.24M |
| Intangibles | 7.42M | 8.36M | 0.00 | 0.00 |
| Other Non-Current Assets | 24.27M | 30.53M | 8.53M | 23.96M |
| Total Non-Current Assets | 34.88M | 42.65M | 14.73M | 30.19M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 127.80M | 157.57M | 149.27M | 144.97M |
| Accounts Payable | 5.50M | 6.98M | 4.20M | 3.20M |
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 1.15M | 0.00 | 0.00 | 349.00K |
| Total Current Liabilities | 40.07M | 47.08M | 38.92M | 20.65M |
| Long Term Debt | 33.72M | 39.23M | 44.44M | 0.00 |
| Deferred Income Taxes | 2.63M | 23.02M | 0.00 | 0.00 |
| Other Non-Current Liabilities | 8.35M | 9.65M | 12.08M | 10.76M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 44.70M | 71.89M | 56.52M | 10.76M |
| Total Liabilities | 84.77M | 118.98M | 95.44M | 31.42M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 43.03M | 38.59M | 53.83M | 113.55M |
| Common Par | 420.00K | 419.00K | 418.00K | 418.00K |
| Additional Paid In Capital | 62.52M | 59.96M | 58.47M | 98.64M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -34.10M | -38.94M | -21.63M | 14.02M |
| Treasury Stock | -1.98M | -700.00K | 0.00 | 0.00 |
| Other Equity Adjustments | 16.17M | 17.85M | 16.57M | 484.00K |
| Total Capitalization | 76.75M | 77.82M | 98.27M | 113.55M |
| Total Equity | 43.03M | 38.59M | 53.83M | 113.55M |
| Total Liabilities & Stock Equity | 127.80M | 157.57M | 149.27M | 144.97M |
| Total Common Shares Outstanding | 41.96M | 41.88M | 41.85M | 41.85M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 457.03K | 186.99K | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 41.66M | 41.84M | 41.85M | 41.84M |
| Diluted Weighted Shares Outstanding | 41.78M | 41.84M | 41.85M | 41.84M |
| Number of Employees | 128 | 108 | 93 | 93 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with SCMP
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Setting Up...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- UserGFNN Stockdiagnostics 5
- User©SUPRATRADE HOT STOCKS (...
Latest SCMP Headlines from TheStreet
- Sucampo Pharmaceuticals Inc. A Stock Upgraded (SCMP) 04.18.13 | 05:04 am
- Most Profitable Second Quarter Biotech Stocks 04.02.13 | 06:04 am
- 5 Stocks Under $10 Triggering Breakouts 03.14.13 | 01:03 pm
- Best And Worst FDA Drug Approval Stocks of 2013 03.12.13 | 08:03 am
- Sucampo Pharmaceuticals Inc. A Stock Downgraded (SCMP) 03.12.13 | 05:03 am
- Play TheStreet's FDA Drug Approval Contest 03.05.13 | 12:03 pm
- TheStreet Ratings Top 10 Rating Changes 01.14.13 | 10:01 am
- Sucampo Pharmaceuticals Inc. A Stock Upgraded (SCMP) 01.14.13 | 04:01 am
- Sucampo Pharmaceuticals Inc. A Stock Upgraded (SCMP) 10.29.12 | 05:10 am
- 5 Stocks Poised for Breakouts 09.28.12 | 01:09 pm
Press Releases for SCMP
- Sucampo Pharmaceuticals, Inc. Reports Fourth Quarter And Full Year 2012 Financial And Operating Results - Business Wire 03.13.13 | 05:03 pm
- Sucampo Pharmaceuticals Announces Fourth Quarter And Full Year 2012 Financial Results And Operating Highlights Teleconference And Webcast - Business Wire 03.06.13 | 06:03 am
- Sucampo Appoints Barbara A. Munder And Maureen E. O’Connell To Board Of Directors - Business Wire 03.01.13 | 06:03 am
- Sucampo Announces Commercial Availability Of RESCULA In U.S. Pharmacies - Business Wire 02.19.13 | 08:02 pm
- Sucampo Files Patent Infringement Lawsuit Against Anchen Pharmaceuticals And Par Pharmaceuticals - Business Wire 02.08.13 | 06:02 am
- Sucampo Pharmaceuticals To Present At Investment Conferences - Business Wire 02.06.13 | 06:02 am
- Sucampo Announces Japanese Government Funding For Unoprostone Isopropyl Development In Retinitis Pigmentosa - Business Wire 02.04.13 | 06:02 am
- Sucampo Pharmaceuticals Announces Webcast Of Its Presentation At The Biotech ShowcaseTM 2013 Conference - Business Wire 01.03.13 | 06:01 am
- Sucampo Announces FDA Approval Of An SNDA For RESCULA® (unoprostone Isopropyl) - Business Wire 12.12.12 | 06:12 am
- Sucampo Receives $15 Million Milestone Payment From Abbott On First Sale Of AMITIZA® (lubiprostone) In Japan - Business Wire 12.11.12 | 06:12 am
Partner Headlines for SCMP
- 5 Pharmaceutical Companies With EMA Or MHRA Catalysts This Year - Seeking Alpha 08.28.12 | 09:08 am
- Phase 3 Long-Term Safety Trial Results of Lubiprostone in Patients with Irritable Bowel Syndrome with Constipation was Recently Published in Alimentary Pharmacology and Therapeutics - Benzinga 03.06.12 | 04:03 pm
- Life Sciences Companies Raise Record Amounts of Capital - Seeking Alpha 12.31.10 | 04:12 pm
